Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

DOI: 10.1136/annrheumdis-2017-212245
Annals of the Rheumatic Diseases, 2018, 77, 914-921.

#	Paper	IF	Citations
77	Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. *Dermatology and Therapy*, **2018**, 8, 173-194	4	32
76	The biosimilars journey: current status and ongoing challenges. *Drugs in Context*, **2018**, 7, 212543	5.2	8
75	Low Percentage of Signal Regulatory Protein Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. *Frontiers in Immunology*, **2018**, 9, 2865	8.4	6
74	Similar Pharmacokinetics of the Adalimumab (Humira) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE-AI and VOLTAIRE-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials. *Rheumatology and Therapy*, **2018**, 5, 403-421	4.4	11
73	Research Techniques Made Simple: Sample Size Estimation and Power Calculation. *Journal of Investigative Dermatology*, **2018**, 138, 1678-1682	4.3	20
72	Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. *Current Rheumatology Reports*, **2018**, 20, 57	4.9	28
71	Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies. *Advances in Therapy*, **2018**, 35, 1295-1332	4.1	15
70	Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). *Expert Opinion on Biological Therapy*, **2019**, 19, 1097-1105	5.4	9
69	Biosimilars for the treatment of psoriatic arthritis. *Expert Review of Clinical Immunology*, **2019**, 15, 1195-1203	3.2	1
68	IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. *Lancet Rheumatology, The*, **2019**, 1, e35-e43	14.2	4
67	Biosimilars in rheumatology. *Pharmacological Research*, **2019**, 149, 104467	10.2	2
66	Era of biosimilars in rheumatology: reshaping the healthcare environment. *RMD Open*, **2019**, 5, e000900	5.9	39
65	Are There Benefits and Risks to Biosimilars from a Patient Perspective?. *Rheumatic Disease Clinics of North America*, **2019**, 45, 465-476	2.4	3
64	Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. *Expert Opinion on Biological Therapy*, **2019**, 19, 1001-1014	5.4	12
63	Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. *BioDrugs*, **2019**, 33, 241-253	7.9	22
62	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Digestive and Liver Disease*, **2019**, 51, 632-639	3.3	22
61	FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. *Arthritis Research and Therapy*, **2019**, 21, 281	5.7	19

60	Bioequivalence studies with anti-TNF biosimilars. *Expert Opinion on Biological Therapy*, **2019**, 19, 1031-1043	5.4	2
59	Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. *Clinical Therapeutics*, **2019**, 41, 155-173.e13	3.5	16
58	Biosimilars of adalimumab: the upcoming challenge in IBD. *Expert Opinion on Biological Therapy*, **2019**, 19, 1023-1030	5.4	13
57	The US Biosimilar Market: Stunted Growth and Possible Reforms. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 92-100	6.1	33
56	Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. *Journal of Dermatological Treatment*, **2020**, 31, 794-800	2.8	15
55	Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar. *Annals of the Rheumatic Diseases*, **2020**, 79, e44	2.4	3
54	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. *BioDrugs*, **2020**, 34, 27-37	7.9	19
53	Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. *International Journal of Rheumatic Diseases*, **2020**, 23, 1514-1525	2.3	3
52	Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. *British Journal of Clinical Pharmacology*, **2020**, 86, 2274-2285	3.8	5
51	Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. *RMD Open*, **2020**, 6,	5.9	8
50	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2020**, 79, 760-770	2.4	112
49	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 734-755	6.1	45
48	Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. *Expert Opinion on Drug Safety*, **2020**, 19, 459-466	4.1	3
47	Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura , Hetero Biopharma Ltd.) and reference adalimumab (Humira , Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy. *BMC Rheumatology*, **2020**,	2.9	3
46	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2020**, 79, 744-759	2.4	75
45	Immunogenicity in Clinical Practice and Drug Development: When is it Significant?. *Clinical and Translational Science*, **2020**, 13, 219-223	4.9	8
44	Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. *American Journal of Clinical Dermatology*, **2020**, 21, 483-491	7.1	9
43	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. *Rheumatology and Therapy*, **2020**, 7, 35-64	4.4	29

42	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. *Drugs*, **2020**, 80, 99-113	12.1	32
41	[Biosimilars: opportunities and risks]. *Der Internist*, **2020**, 61, 522-529	0	1
40	Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. *Rheumatology and Therapy*, **2021**, 8, 41-61	4.4	10
39	Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. *Expert Opinion on Biological Therapy*, **2021**, 21, 87-96	5.4	2
38	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. *Expert Review of Clinical Immunology*, **2021**, 17, 85-99	5.1	8
37	Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. *Expert Opinion on Biological Therapy*, **2021**, 21, 57-73	5.4	3
36	A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra) in Chinese healthy subjects. *Annals of Medicine*, **2021**, 53, 375-383	1.5	1
35	The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study). *Nauchno-Prakticheskaya Revmatologiya*, **2021**, 58, 663-672	0.9	1
34	A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men. *Frontiers in Pharmacology*, **2020**, 11, 609522	5.6	1
33	Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults. *Therapeutic Advances in Musculoskeletal Disease*, **2021**, 13, 1759720X211002685	3.8	1
32	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. *Arthritis Research and Therapy*, **2021**, 23, 51	5.7	11
31	Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. *Modern Rheumatology*, **2021**, 1-13	3.3	1
30	Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. *Frontiers in Immunology*, **2021**, 12, 638444	8.4	2
29	Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. *Annals of the Rheumatic Diseases*, **2021**,	2.4	2
28	Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. *Rheumatology*, **2021**, 60, 5247-5256	3.9	6
27	Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis. *Zeitschrift Fur Rheumatologie*, **2021**, 1	1.9	1
26	Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 2324-2332.e6	6.9	4
25	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomised study in rheumatoid arthritis. *Rheumatology*, **2021**,	3.9	4

24	Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis. *Zeitschrift Fur Rheumatologie*, **2021**, 1	1.9	0
23	An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability. *Drug Design, Development and Therapy*, **2021**, 15, 2987-2998	4.4	2
22	Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 816-825	18.8	6
21	Immunogenicity Assessment of Biosimilars: A Multidisciplinary Perspective. *AAPS Advances in the Pharmaceutical Sciences Series*, **2018**, 489-542	0.5	3
20	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. *Current Pharmaceutical Design*, **2019**, 25, 7-12	3.3	6
19	Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review. *British Journal of Clinical Pharmacology*, **2021** ,	3.8	2
18	Regulatory Perspectives on Biopharmaceuticals for Chronic Inflammatory Diseases in North Africa: A Narrative Review. *Open Rheumatology Journal*, **2019**, 13, 72-84	0.2	
17	Rheumatic Diseases and Biosimilars: Evidence about Switch from Originators to Biosimilars in the Real Life.		
16	[Use of biosimilars in the treatment of rheumatoid arthritis : An overview]. *Zeitschrift Fur Rheumatologie*, **2021**, 1	1.9	
15	A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).. *Expert Opinion on Investigational Drugs*, **2022**, 1-12	5.9	2
14	Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis.. *Journal of Personalized Medicine*, **2022**, 12,	3.6	0
13	Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients' satisfaction: a cross-sectional survey by patient organisations.. *BMJ Open*, **2022**, 12, e050949	3	0
12	Ozoralizumab, a Humanized Anti-TNF NANOBODY Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNF IgG.. *Frontiers in Immunology*, **2022**, 13, 853008	8.4	1
11	An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.. *Ophthalmology and Therapy*, **2022**,	5	1
10	Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis.. *ACS Chemical Biology*, **2022**,	4.9	0
9	Data_Sheet_1.docx. **2018**,		
8	Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. *Intestinal Research*,	4.1	1
7	The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study. *Rheumatology and Therapy*,	4.4	0

6	Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. *Advances in Therapy*,	4.1	
5	Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial. *Clinical Rheumatology*,	3.9	
4	The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.		0
3	Korean clinical practice guidelines on biologics for moderate to severe Crohn disease.		0
2	Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge. 66-74		1
1	A Review of Adalimumab Biosimilars for the Treatment of Immune-Mediated Rheumatic Conditions. 122-133		0